Antibodies to Glutamic Acid Decarboxylase in Japanese Diabetic Patients with Secondary Failure of Oral Hypoglycaemic Therapy

1997 ◽  
Vol 14 (2) ◽  
pp. 148-152 ◽  
Author(s):  
M. Fukui ◽  
K. Nakano ◽  
H. Shigeta ◽  
K. Yoshimori ◽  
M. Fujii ◽  
...  
2003 ◽  
Vol 16 (2) ◽  
pp. 129-138
Author(s):  
C. Konidaris ◽  
P.G. Mitlianga ◽  
G.K. Papadopoulos

The 65 kD isoform of Glutamic Acid Decarboxylase (GAD), is one of the major autoantigens in human type 1 diabetes mellitus. This enzyme shares aminoacid identity, in select regions already determined as antigenic with its counterpart from E. coli. We tested the reactivity of diabetic and normal sera and an E. coli GAD-specific monoclonal antibody (2D9) to E. coli GAD by solid phase and competition ELISA, as well as immunoblotting to check for cross-reactivity of autoantibodies to the two antigens. Specific antibodies for E. coli GAD are present in diabetics and normal subjects without any differences in frequency and titer. The reactivity of such antibodies in ELISA could be blocked in a dose-dependent manner by the addition of excess antigen in the liquid phase. Furthermore, the monoclonal antibody against E. coli GAD does not recognise human recombinant GAD65 in an ELISA. We conclude that there is no basis for cross-reactivity between the two antigens, and antibody reactivity to GAD65 in man cannot arise from cross-reactivity to the E. coli enzyme.


2002 ◽  
Vol 57 (3) ◽  
pp. 171-177 ◽  
Author(s):  
Alan Leslie Todd ◽  
Wai-Yoong Ng ◽  
Yung Seng Lee ◽  
Kah Yin Loke ◽  
Ah Chuan Thai

2005 ◽  
Vol 99 (2) ◽  
pp. 180-185 ◽  
Author(s):  
Michiyo Ishii ◽  
Goji Hasegawa ◽  
Michiaki Fukui ◽  
Hiroshi Obayashi ◽  
Mitsuhiro Ohta ◽  
...  

2019 ◽  
Vol 9 (3) ◽  
pp. 213-217
Author(s):  
Nazimul Islam ◽  
Tanjima Begum ◽  
Ashesh Kumar Chowdhury ◽  
Umarah Miazi ◽  
Md Soharab Alam ◽  
...  

Background: Many patients with type 2 diabetes mellitus (T2DM) test positive for glutamic acid decarboxylase (GAD).These individuals have been referred to as having latent autoimmune diabetes in adults (LADA) or type 1.5 diabetes. LADA refers to a specific type of diabetes affecting adult patients, characterized by presence of islet auto-antibodies, insulin independence at the time of diagnosis and characterized by slower beta cell destruction. The aim of this study was to indentify GAD positivity in a selected group of Bangladeshi T2DM patients and compare the clinical characteristics of GAD positive and negative subjects. Methods: This cross-sectional study was conducted in 2017 at BIRDEM General Hospital, Dhaka. Recently diagnosed drug-naive patients with T2DM were evaluated. Considering inclusion and exclusion criteria 100 subjects were screened. These patients allowed for the assessment of GAD positivity along with anthropometric and biochemical characteristics. Results: A total of 100 newly diagnosed (within 6 months) T2DM patients in age group 30-70 years were selected for this study. Of them men and women were 59.6% and 40.4% respectively. The GAD antibody positive was found to be 10%. There was no significant difference in respect of age, body mass index, fasting plasma glucose, HbA1c, total cholesterol, triglycerides, HDL cholesterol, LDL and blood pressure between GAD positive and GAD negative subjects. Conclusion: The presence of GAD positivity was 10% among adult patients with newly diagnosed T2DM which wasvery high in Bangladeshi population. Further long term prospective studies need to be essential to identify the actual situation of GAD positive subjects and to determine their clinical course and optimal treatment regimens. Birdem Med J 2019; 9(3): 213-217


Sign in / Sign up

Export Citation Format

Share Document